NewSquare Capital’s Foghorn Therapeutics FHTX Stock Holding History

NewSquare Capital’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,000	Closed	-$62K	–	886
2023 Q1	$62K	Hold	10,000	–	–	0.01%	185
2022 Q4	$63.8K	Hold	10,000	–	–	0.01%	170
2022 Q3	$86K	Hold	10,000	–	–	0.01%	164
2022 Q2	$136K	Hold	10,000	–	–	0.02%	160
2022 Q1	$152K	Buy	+10,000	New	+$137K	0.02%	165
2021 Q3	–	Sell	-5,000	Closed	-$53K	–	363
2021 Q2	$53K	Buy	+5,000	New	+$54.5K	0.01%	193

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NewSquare Capital's FHTX Position: Q2 2023 in Review

NewSquare Capital sold out of Foghorn Therapeutics (FHTX) in Q2 2023, closing a stake of 10,000 shares — an estimated $62K sold.

NewSquare Capital first reported a position in FHTX in Q2 2021 and held it in 6 quarters. The position peaked at $152K in Q1 2022. 59 funds tracked by Wall St. Rank hold FHTX as of Q2 2023.

NewSquare Capital reported no remaining Foghorn Therapeutics position as of Q2 2023 after selling out during the quarter.
NewSquare Capital sold 10,000 Foghorn Therapeutics shares in Q2 2023, an estimated $62K.
NewSquare Capital first reported a position in Foghorn Therapeutics in Q2 2021 and held it in 6 quarters.
NewSquare Capital's Foghorn Therapeutics position peaked at $152K in Q1 2022.
59 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2023.

Based on NewSquare Capital's 13F filing for Q2 2023, filed 3 Aug 2023.